Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

KalVista Pharmaceuticals (KALV) Retained Earnings: 2014-2024

Historic Retained Earnings for KalVista Pharmaceuticals (KALV) over the last 6 years, with Dec 2024 value amounting to -$580.2 million.

  • KalVista Pharmaceuticals' Retained Earnings was N/A to -$580.2 million in Q4 2024 from the same period last year, while for Dec 2024 it was -$580.2 million, marking a year-over-year change of. This contributed to the annual value of -$469.7 million for FY2024, which is N/A change from last year.
  • According to the latest figures from Q4 2024, KalVista Pharmaceuticals' Retained Earnings is -$580.2 million, which was down 5.02% from -$552.4 million recorded in Q4 2024.
  • In the past 5 years, KalVista Pharmaceuticals' Retained Earnings ranged from a high of -$115.0 million in Q1 2020 and a low of -$580.2 million during Q4 2024.
  • Its 2-year average for Retained Earnings is -$471.7 million, with a median of -$469.7 million in 2024.
  • Data for KalVista Pharmaceuticals' Retained Earnings shows a maximum YoY crashed of 39.49% (in 2024) over the last 5 years.
  • Over the past 4 years, KalVista Pharmaceuticals' Retained Earnings (Quarterly) stood at -$142.8 million in 2020, then tumbled by 32.93% to -$152.9 million in 2021, then reached -$396.0 million in 2023, then slumped by 39.49% to -$580.2 million in 2024.
  • Its Retained Earnings stands at -$580.2 million for Q4 2024, versus -$552.4 million for Q4 2024 and -$510.2 million for Q3 2024.